Literature DB >> 34529489

The adaptive immune system is a major driver of selection for tumor suppressor gene inactivation.

Timothy D Martin1, Rupesh S Patel1, Danielle R Cook2,3, Mei Yuk Choi1, Ajinkya Patil1, Anthony C Liang1, Mamie Z Li1, Kevin M Haigis2,3, Stephen J Elledge1.   

Abstract

During tumorigenesis, tumors must evolve to evade the immune system and do so by disrupting the genes involved in antigen processing and presentation or up-regulating inhibitory immune checkpoint genes. We performed in vivo CRISPR screens in syngeneic mouse tumor models to examine requirements for tumorigenesis both with and without adaptive immune selective pressure. In each tumor type tested, we found a marked enrichment for the loss of tumor suppressor genes (TSGs) in the presence of an adaptive immune system relative to immunocompromised mice. Nearly one-third of TSGs showed preferential enrichment, often in a cancer- and tissue-specific manner. These results suggest that clonal selection of recurrent mutations found in cancer is driven largely by the tumor’s requirement to avoid the adaptive immune system.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34529489     DOI: 10.1126/science.abg5784

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  22 in total

1.  Air pollution particles hijack peroxidasin to disrupt immunosurveillance and promote lung cancer.

Authors:  Zhenzhen Wang; Ziyu Zhai; Chunyu Chen; Xuejiao Tian; Zhen Xing; Panfei Xing; Yushun Yang; Junfeng Zhang; Chunming Wang; Lei Dong
Journal:  Elife       Date:  2022-04-19       Impact factor: 8.140

2.  EMSY inhibits homologous recombination repair and the interferon response, promoting lung cancer immune evasion.

Authors:  Antonio Marzio; Emma Kurz; Jennifer M Sahni; Giuseppe Di Feo; Joseph Puccini; Shaowen Jiang; Carolina Alcantara Hirsch; Arnaldo A Arbini; Warren L Wu; Harvey I Pass; Dafna Bar-Sagi; Thales Papagiannakopoulos; Michele Pagano
Journal:  Cell       Date:  2021-12-27       Impact factor: 41.582

Review 3.  Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers.

Authors:  Alicia Cristina Peña-Romero; Esteban Orenes-Piñero
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

4.  m6A Regulator-Mediated Methylation Modification Patterns and Characterisation of Tumour Microenvironment Infiltration in Non-Small Cell Lung Cancer.

Authors:  Yongfei Fan; Yong Zhou; Ming Lou; Xinwei Li; Xudong Zhu; Kai Yuan
Journal:  J Inflamm Res       Date:  2022-03-23

Review 5.  Clinical relevance of tumour-associated macrophages.

Authors:  Mikael J Pittet; Olivier Michielin; Denis Migliorini
Journal:  Nat Rev Clin Oncol       Date:  2022-03-30       Impact factor: 66.675

6.  MDM2/MDM4 amplification and CDKN2A deletion in metastatic melanoma and glioblastoma multiforme may have implications for targeted therapeutics and immunotherapy.

Authors:  Taylor E Arnoff; Wafik S El-Deiry
Journal:  Am J Cancer Res       Date:  2022-05-15       Impact factor: 5.942

7.  Glioblastoma: The Current State of Biology and Therapeutic Strategies.

Authors:  Zev A Binder; Donald M O'Rourke
Journal:  Cancer Res       Date:  2022-03-01       Impact factor: 13.312

8.  ZBTB28 inhibits breast cancer by activating IFNAR and dual blocking CD24 and CD47 to enhance macrophages phagocytosis.

Authors:  Li Li; Yijia Gong; Jun Tang; Chun Yan; Lili Li; Weiyan Peng; Zhaobo Cheng; Renjie Yu; Qin Xiang; Chaoqun Deng; Junhao Mu; Jiuyi Xia; Xinrong Luo; Yongzhong Wu; Tingxiu Xiang
Journal:  Cell Mol Life Sci       Date:  2022-01-20       Impact factor: 9.261

9.  A new perspective on immune evasion: escaping immune surveillance by inactivating tumor suppressors.

Authors:  Svenja Mergener; Samuel Peña-Llopis
Journal:  Signal Transduct Target Ther       Date:  2022-01-13

Review 10.  Novel Therapeutic Targets and Immune Dysfunction in Malignant Pleural Mesothelioma.

Authors:  Moshe Lapidot; Srinivas Vinod Saladi; Ravi Salgia; Martin Sattler
Journal:  Front Pharmacol       Date:  2022-01-07       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.